



3

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |    |   |
|--|--|----|---|
| (51) International Patent Classification <sup>4</sup> :<br><b>G01N 33/569, 33/543, C12N 15/00<br/>C12P 21/00, C07K 15/00</b> |  | A1 | (11) International Publication Number: <b>WO 87/ 05399</b>                  |
|  |  |    | (43) International Publication Date:<br><b>11 September 1987 (11.09.87)</b> |

|   |   |
|---|---|
| (21) International Application Number: <b>PCT/US87/00373</b>  | (81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). |
| (22) International Filing Date: <b>20 February 1987 (20.02.87)</b>  |   |
| (31) Priority Application Number: <b>834,212</b>  |   |
| (32) Priority Date: <b>27 February 1986 (27.02.86)</b>  |   |
| (33) Priority Country: <b>US</b>  |   |
| (71) Applicant: CENTOCOR, INC. [US/US]; 244 Great Valley Parkway, Malvern, PA 19355 (US).   |   |
| (72) Inventors: CHANG, Nancy, T. : 7405 Brompton, Houston, TX 77025 (US). GHRAYEB, John : 3202 Raye Road, Thorndale, PA 19372 (US). |   |
| (74) Agents: DeCONTI, Giulio, A., Jr. et al.: Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US).       |   |

## Published

*With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

EPA EPO-OEB

DG 1

Requ:

15 SEP 1987

## (54) Title: METHOD OF DETECTING ANTIBODY AGAINST HTLV-III

## (57) Abstract

Immunochemical assays for detection of antibodies against HTLV-III core proteins. The assays are based upon recombinant HTLV-III core proteins expressed by cloned DNA segments of the gag region of the HTLV-III genome. Immunoreactive, chimeric HTLV-III core proteins and methods of producing these proteins are also described.

METHOD OF DETECTING ANTIBODY AGAINST HTLV-IIIField of the Invention

This invention is in the fields of immunology and virology and pertains to immunochemical detection of AIDS virus infection based upon recombinant 05 HTLV-III core antigens.

Background of the Invention

Since the identification of human T cell lymphotropic virus Type III (HTLV-III) (also called 10 lymphadenopathy virus (LAV) or AIDS-associated retrovirus (ARV)) as the probable cause of infectious Acquired Immunodeficiency Syndrome (AIDS) and the establishment of a permissive T cell line for mass production of the virus, substantial progress 15 has been made in characterizing the virus. The complete nucleotide sequence of molecular clones of various provirus isolates have been deciphered. See Ratner *et al.*, (1985) Nature 313, 277-284; Wain- 20 Hobson *et al.*, (1985) Cell 40, 9-17; Sanches- Pescador *et al.*, (1985) Science 227, 484-492; Muesing *et al.*, (1985) Nature 313, 450-458. The provirus is 9734-9749 base pairs (bp) in length including two long terminal repeat (LTR) sequences. HTLV-III contains many characteristic structural 25 features of other retroviruses: the long terminal repeats, a core protein gene (gag), a gene region (pol) encoding the virion RNA-dependent DNA

-2-

polymerase and a gene encoding the virus envelope glycoproteins (env). Unlike other retroviruses the HTLV-III viruses contain two additional small open reading frames (5'ORF and 3'ORF) which may play a 05 role in its unusual cytopathogenicity. See Ratner et al., supra.

HTLV-III gag proteins are synthesized in the form of a polyprotein precursor of 512 amino acids which is proteolytically processed to individual gag 10 proteins p17, p24 and p15. Data obtained from the analysis of nucleotide structure and the gag gene products of HTLV-III and ARV indicate that the p17, p24 and p15 proteins are 134, 230 and 122 amino acids long respectively. See Ratner et al., Wain- 15 Hobson et al., Sanchez-Pescador et al., and Muesing et al., supra. Two precursors, p70 and p55, have been detected in HTLV-III infected cells in culture and were shown to share peptide homology with the p24 gag protein Roby et al., (1985). Recently the 20 p24 protein has been isolated from HTLV-III. Casey J.M., et al., (1985), J. Virol., 55 (2), 417-423.

Several methods for the detection of HTLV-III infection also have been developed. Solid-phase immunoassays employing inactivated HTLV-III as a 25 whole virus antigen immunoadsorbent have been developed for the detection of antibodies against HTLV-III in sera of patients. Such assays have been shown to detect antibodies in more than 80% of sera from patients with AIDS or AIDS-related complex 30 (ARC), or from individuals infected with HTLV-III

-3-

and these are useful for diagnosing AIDS and for screening contaminated blood.

Assays employing the whole virus, however, have several drawbacks. Large quantities of the virus 05 must be cultivated as supply for test reagents. Although rigorous safety measures can be instituted, there are dangers associated with large scale cultivation of the infectious virus. Further, there exists a risk, however small, that test reagents 10 prepared with the inactivated virus can be contaminated with live virus. Thus, persons who handle the reagents may be subjected to the risk of HTLV-III infection.

Isolated viral p24 protein has been used in an 15 immunoprecipitation assay for detection of anti-HTLV-III antibody in sera of AIDS patients. High serum titer of antibody was found in 73% AIDS patients. Casey, J.M., et al., supra. Assays employing isolated viral components such as the p24 20 protein, however, do not eliminate the need for production of the virus. Large scale production of the virus is required for isolation of sufficient quantity of the viral protein for preparation of assay reagents.

25 Disclosure of the Invention

This invention pertains to recombinant HTLV-III 20 antigenic polypeptides expressed by cloned DNA segments of the gag region of the HTLV-III genome and to immunochemical assays for detecting antibody 30 against HTLV-III core protein employing the

polypeptides. The recombinant HTLV-III core proteins are immunoreactive with anti-HTLV-III core protein antibodies in the serum HTLV-III infected individuals. Because of this, the recombinant core proteins can be used to detect antibodies against HTLV-III core proteins in a biological fluid. In addition, they can be used in conjunction with immunoreactive recombinant HTLV-III envelop proteins for combined assay of antibody against HTLV-III core and envelop protein.

Three HTLV-III recombinant core antigens were expressed in bacterial cells. Restriction fragments of HTLV-III gag gene were cloned into E. coli. (Strain JA221) cells to produces three clonal cell lines. One clonal cell line, designated pG1, produces a hybrid protein containing 13 amino acid residues on the C-terminal of the 17Kd virion protein, the entire p24 polypeptide and 74 amino acid residues of the amino terminal of the 15Kd core ribonucleoprotein. The second clone, pG2, produces a protein similar to pG1 except that it contains no p17 sequences and lacks the NH<sub>2</sub>-terminal 77 amino acid residues of the p24. The third clone pG3 expresses a protein similar to pG2 except all but 56 amino acids of the C-terminal of p24 are absent. Thus, the antigens are chimeric molecules made up of portions of the virion p17, p24 and p15 core proteins.

The recombinant proteins are expressed by these clones as fusion proteins made up of the HTLV-III polypeptide (encoded by the cloned the gag gene

segment) flanked by exogenous (vector supplied) polypeptide elements at the amino and carboxyl terminals. The fusion proteins pG1, pG2 and pG3 are strongly reactive towards anti-gag protein anti-  
05 bodies present present in pooled sera from AIDS patients. The immunoreactivity of the pG1, pG2, and pG3 proteins indicates that strong antigenic determinants are present between amino acid residues 77 and 175 of the viral p24 protein and residues 1 and  
10 74 of the p15 protein.

The bacterially expressed pG2 protein can be purified to virtual homogeneity. This can be accomplished by dissolution of the protein in a buffer containing a strong denaturant (8M Urea) and by  
15 subsequent dialysis and repetitive gel filtration chromatography in the presence of the denaturant. The pG2 protein purified by this technique is immunoreactive with antibody in AIDS patient sera. In strip assays, detection of anti-p24 antibody by  
20 pG2 protein correlates with detection of the antibody with whole virus.

The recombinant core antigens provide immunochemical methods for detection of antibody against HTLV-III core proteins. Immunochemical assays for  
25 detection of antibody against HTLV-III core protein can take several forms, including immunometric assays and antigen sandwich assays. The preferred type of assay is a solid phase immunometric (double antibody) assay. The purified gag derived polypeptide is immobilized by attaching it to solid phase  
30 to form an antigen immunoabsorbent.

The immunoadsorbent is used to adsorb anti-HTLV-III core protein antibody in a sample of the biological fluid. The adsorbed anti-HTLV-III antibody is detected with an anti-(human IgG) antibody which is 05 labeled radioisotopically, enzymatically, fluorometrically or in other ways. This second antibody, directed generally against human IgG, binds to anti-HTLV-III antibody adsorbed to the immuno-adsorbent and provides a detectable signal which can 10 be evaluated as an indication of the presence of anti-HTLV-III core protein antibody in the sample.

HTLV-III core protein can be used in conjunction with HTLV-III envelop proteins (e.g. HTLV-III polypeptide 121) to enhance detection of antibody 15 against the virus. For this purpose, the approximately equimolar amounts of the core protein (e.g. pG2) and the envelope protein can be affixed to a solid phase to form a dual antigen immuno-adsorbent for use in an immunometric assay.

20 Expression of the pG1, pG2 and pG3 proteins in bacterial cells and demonstration of the immunoreactivity of these proteins establishes that the antigenicity of HTLV-III core proteins can be retained when the proteins are expressed in a host 25 cell system. Further, expression of these proteins enabled identification of certain antigenic regions of p24 and p15 which can aid in rational design of additional recombinant HTLV-III core antigens. For example, other chimeric core proteins which embody 30 these antigenic protein domains can be produced.

Immunochemical assays employing the gag derived polypeptides for detection of anti-HTLV-III core protein antibodies provide several advantages over those based on the whole virus or on isolated viral components. Viral components produced in safe host cells eliminate the need to grow large quantity of the infectious virus for preparation of assay reagents. This alleviates the risk associated with this process. Assay reagents based upon the HTLV-III antigens rather than the whole virus will help mitigate the real or perceived risk of contracting AIDS by technicians who perform the assay. Additionally, homogenous preparations of core protein can provide for less variability in assay performance. In whole virus preparation the level of core protein may vary and affect the sensitivity of the assay.

Brief Description of the Drawings

Figure 1 is a schematic representation of the construction of the HTLV-III gag gene clones

Figure 2 shows SDS-PAGE analysis of HTLV-III gag gene hybrid proteins, pG1, pG2 and pG3.

Figure 3 shows a Western blot analysis of the immunoreactivity of the pG1, pG2 and pG3 HTLV-III gag gene clones.

Figure 4 shows SDS-PAGE analysis of purified pG2.

Figure 5 shows the predicted amino acid sequence for the pG2 protein.

Figure 6 illustrates RIA results for antibodies against purified pG2 protein in sera from AIDS/ARC patients and healthy individuals.

Best Mode of Carrying out the Invention

05 Three recombinant HTLV-III core proteins, designated pG1, pG2 and pG3 were produced by cloning and expressing three segments of DNA from the gag gene of HTLV-III in E. Coli. The gag gene of HTLV-III is capable of encoding a protein of 512 10 amino acid residues. The p17 protein spans amino acid residues 1-132, the p24 is derived from amino acid residues 133-363 and the p15 from amino acid residues 378-512. Amino acids 364-377 are not present in processed, mature viral gag proteins, but 15 are present in pG1, pG2 and pG3 proteins.

The segments were obtained by restriction endonuclease digestion of HTLV-III DNA. HTLV-III DNA was excised by Sst I digestion from  $\lambda$ BH-10, a recombinant phage comprising a 9 kb segment of the 20 HTLV-III genome inserted into the vector  $\lambda$ gt WES $\lambda$ B. See B.H. Haha et al., Nature, 312, 166 (1984). The Sst I fragment is shown with the nucleotide numbers above the restriction enzyme designation in Figure 1.

The pG1, pG2 and pG3 gene constructs were made 25 by further digestion of the Sst I fragment. The three constructs are illustrated schematically in Figure 1. The Sst I fragment from  $\lambda$ BH-10 was digested with the restriction endonucleases Pvu II and Bgl II or Pst I and Bgl II. Pvu II/Bgl II 30 digestion yielded a 949 bp fragment (corresponding

to nucleotide 692 through 1641 of the HTLV-III genome) and Pst I/Bgl II digestion gave a 677 bp fragment (nucleotides 964-1641). The fragments were inserted into a the "REV" expression vector (Rep-05 ligen, Cambridge, MA) to give plasmid pG1 and pG2, respectively.

Plasmid pG3 was constructed from pG2. pG2 DNA was digested with Pst I and Hind III, end repaired and ligated, resulting in excision of the Pst I-Hind 10 III fragment from pG2.

E. coli cells were transformed with the recombinant vectors. Bacterial cells containing the plasmids pG1, pG2 and pG3 expressed proteins of 41Kd, 33Kd and 18Kd, respectively. The expressed 15 proteins were fusion proteins containing a methionine residue plus 33 vector encoded amino acid residues at the NH<sub>2</sub> terminal of the HTLV-III polypeptide and 14 vector encoded amino acids at the COOH terminal. The fusion proteins were made in 20 large quantities by the transformed bacterial cell lines (over 10% of total cellular protein). The expressed fusion proteins were tested for reactivity with pooled AIDS patient sera by Western blot analysis. Each protein was immunoreactive.

25 The immunoreactivity of the pG1, pG2 and pG3 proteins indicate that these proteins exhibit strong HTLV-III antigenic determinants. The determinants are present between amino acid residues 77-175 of p24 protein and residues 1-74 of the p15 proteins.

-10-

The pG2 protein was purified to greater than 98% homogeneity by the following procedure. Soluble cellular protein was removed from pG2 cell lysates by extraction with a nondenaturant buffer. The 05 fusion protein pG2 was contained in the insoluble cell pellet at approximately 20% purity. The pG2 protein was solubilized by suspending the cell pellet in an extraction buffer comprising 50 mM Tris-HCl, 8 M Urea, 1M NaCl, 10mM DL dithiothreitol 10 (DTT) and 0.05% EDTA disodium salt. The suspension was homogenized and centrifuged. pG2 in the supernatant was purified by gel filtration chromatography in the extraction buffer, subsequent dialysis against distilled water, and further gel filtration 15 chromatography in the extraction buffer. The major peak eluted from final gel filtration column contained the pG2 protein at greater than 98% purity as judged by SDS-PAGE.

Purified pG2 protein was used in a strip 20 immunoassay to characterize sera from healthy individuals in the high risk population and sera from patients with AIDS or ARC. pG2 protein adsorbed onto nitrocellulose strips was incubated with human serum to be tested, washed, then contacted 25 with labeled anti-human IgG to detect antibody bound to the strip. The assay was also performed with disrupted whole virus. pG2 was equally as effective as the whole virus in detecting anti-core protein antibody in sera (100% correlation). Of seropositive 30 healthy homosexuals tested (i.e. those showing antibody reactive with the whole virus), 81% had

antibodies reactive with pG2; the percentage dropped to 56% for AIDS and ARC patients.

The pG1, pG2 and pG3 proteins are hybrid proteins containing parts of naturally occurring 05 HTLV-III antigens (i.e. the viral p17, p24 and p15 core proteins). The success achieved in expression of the immunoreactive chimeric core proteins pG1, pG2 and pG3 indicate that the p17, p24 and p15 proteins themselves can be expressed in host cell 10 systems. In addition, other chimeric HTLV-III core proteins, especially proteins which encompass the identified antigenic domains of the virion proteins p24 and p15 can be produced. Further, the DNA segments encoding these polypeptides may be modified 15 (e.g., by deletion, insertion or substitution of nucleotides) to design other HTLV-III core polypeptides. As used herein, the term "recombinant core protein" is intended to be inclusive all forms of viral core polypeptides which are expressed by 20 genetically engineered host cells and which are immunoreactive with anti-core protein antibody.

Recombinant HTLV-III core proteins, including the pG1, pG2 and pG3 polypeptides, or equivalent type polypeptides can be produced de novo by recom- 25 binant DNA techniques. HTLV-III now can be rou- tinely and reproducibly isolated from patients with AIDS and propagated in a line of permissive T cells developed for this purpose. M. Popovic et al. 30 Science 224, 497 (1984); R. C. Gallo et al. Science 224, 500 (1984). From such cells HTLV-III proviral

DNA can be obtained and cloned. The designated gag regions of the HTLV-III genome, identified to encode antigenic determinants, can be excised from the proviral DNA (generally by restriction enzyme 05 digestion), inserted into an expression vector, preferably one which can express the polypeptide at high levels, to form a recombinant expression vector containing gag gene sequence. Appropriate host cells transformed by the vector can provide a system 10 for expression of the gene product.

Alternatively, gag DNA segments encoding antigenic regions of the core proteins can be synthesized chemically. Several techniques are available for synthesizing DNA of desired nucleotide 15 sequences. See, e.g., Matteucci et al., J. Am. Chem. Soc. (1981) 103:3185; Alvarado-Urbina et al., Science (1980) 214:270. Synthesized segments of viral DNA can be adapted and inserted into an expression vector which can be used to transform vector compatible 20 host cells and provide for expression of the gene product.

Core proteins containing the identified antigenic regions of p24 and p15 can be synthesized chemically. The predicted amino acid sequence of the 25 pG2 protein, for example, is shown in Figure 5; the protein, or proteins, thereof, can be synthesized by the solid phase procedure of Merrifield.

When expressed as heterologous protein in a host cell system, any of several purification 30 techniques, in addition to the techniques described herein for purification of pG2, can be used to

purify the recombinant core proteins. For use in immunoassays, the protein must be purified to substantial immunological purity. Importantly, the preparation should be free of host cell contaminants 05 which might be reactive with antibody in human sera. Such contaminants could yield a high level of false positive results which would detract from the accuracy of the assay.

Immunochemical assays employing the polypeptides 10 can take a variety of forms. The preferred type is a solid phase immunometric assay. In assays of this type, the purified recombinant polypeptide is immobilized on a solid phase to form an antigen-immunoadsorbent. The immunoadsorbent is incubated 15 with the sample to be tested. The duration and conditions of the incubation are standard, those appropriate for the formation of the antigen-antibody complex. The immunoadsorbent is then separated from the sample and a labeled anti-(human IgG) antibody 20 is used to detect human anti-HTLV-III antibody bound to the immunoadsorbent. The amount of label associated with the immunoadsorbent is compared to positive and negative controls to assess the presence or absence of anti-HTLV-III antibody.

25 The immunoadsorbent can be prepared by adsorbing or coupling purified polypeptide to a solid phase. Various solid phases can be used, such as beads formed of glass, polystyrene, polypropylene, dextran or other material. Other suitable solid 30 phases include tubes or plates formed from or coated with these materials.

The recombinant core proteins can be either covalently or non-covalently bound to the solid phase by techniques such as covalent bonding via an amide or ester linkage or adsorption. After the 05 HTLV-III polypeptide is affixed to the solid phase, the solid phase can be post-coated with an animal protein, e.g., 3% fish gelatin. This provides a blocking protein which reduces nonspecific adsorption of protein to the immunoadsorbent surface.

10 The immunoadsorbent functions to insolubilize anti-core protein antibody in the liquid sample tested. In blood screening for anti-HTLV-III antibody, the immunoadsorbent is incubated with blood plasma or serum. Before incubation, plasma or 15 serum is diluted with normal animal plasma or serum. The diluent plasma or serum is derived from the same animal species that is the source of the anti-(human IgG) antibody. The preferred anti-(human IgG) antibody is goat anti-(human IgG) antibody. Thus, 20 in the preferred format, the diluent would be goat serum or plasma. The optimal dilution factor for human plasma and serum is about 10-11 fold.

The conditions of incubation, e.g. pH and temperature, and the duration of incubation are not 25 crucial. These parameters can be optimized by routine experimentation. Generally, the incubation will be run for 1-2 hours at about 45°C in a buffer of pH 7-8.

30 After incubation, the immunoadsorbent and the sample are separated. Separation can be accomplished by any conventional separation technique

such as sedimentation or centrifugation. The immunoadsorbent then may be washed free of sample to eliminate any interfering substances.

To assess human antibody bound to the immuno-  
05 adsorbent, the immunoadsorbent is incubated with the labeled anti-(human IgG) antibody (tracer). Generally, the immunoadsorbent is incubated with a solution of the labeled anti-(human IgG) antibody which contains a small amount (about 1%) of the  
10 serum or plasma of the animal species which serves as the source of the anti-(human IgG) antibody. Anti-(human IgG) antibody can be obtained from any animal source. However, goat anti-(human IgG) antibody is preferred. The anti-(human IgG) anti-  
15 body can be an antibody against the  $F_c$  fragment of human IgG, for example, goat anti-(human IgG)  $F_c$  antibody.

The anti-(human IgG) antibody or anti-(human IgG)  $F_c$  can be labeled with a radioactive material  
20 such as  $^{125}I$ odine; labeled with an optical label, such as a fluorescent material; or labeled with an enzyme such as horse radish peroxidase. The anti-human antibody can also be biotinylated and labeled avidin used to detect its binding to the immuno-  
25 adsorbent.

After incubation with the labeled antibody, the immunoadsorbent is separated from the solution and the label associated with the immunoadsorbent is evaluated. Depending upon the choice of label, the  
30 evaluation can be done in a variety of ways. The label may be detected by a gamma counter if the

label is a radioactive gamma emitter, or by a fluorimeter, if the label is a fluorescent material. In the case of an enzyme label detection may be done colorimetrically employing a substrate for the 05 enzyme.

The amount of label associated with the immuno-adsorbent is compared with positive and negative controls in order to determine the presence of anti-HTLV-III core protein antibody. The controls 10 are generally run concomitantly with the sample to be tested. A positive control is a serum containing antibody against HTLV-III core protein; a negative control is a serum from healthy individuals which do not contain antibody against HTLV-III core protein.

15 For convenience and standardization, reagents for the performance of the immunometric assay can be assembled in assay kits. A kit for screening blood, for example, can include:

- \* a) an immuno-adsorbent e.g. a polystyrene bead 20 coated with a recombinant HTLV-III core polypeptide;
- b) a diluent for the serum or plasma sample, e.g. normal goat serum or plasma;
- c) an anti-(human IgG) antibody e.g. goat 25 anti-(human IgG) antibody in buffered, aqueous solution containing about 1% goat serum or plasma;
- d) a positive control i.e. serum containing antibody against polypeptide 121; and

e) a negative control e.g. pooled sera from healthy individuals which does not contain antibody against polypeptide 121.

If the label is an enzyme, an additional element of 05 the kit can be the substrate for the enzyme.

Another type of assay for anti-HTLV-III antibody is an antigen sandwich assay. In this assay, a labeled HTLV-III recombinant polypeptide is used in place of anti-(human IgG) antibody to detect anti-10 HTLV-III antibody bound to the immunoadsorbent. The assay is based in principle on the bivalence of antibody molecules. One binding site of the antibody binds the antigen affixed to the solid phase; the second is available for binding the labeled 15 antigen. The assay procedure is essentially the same as described for the immunometric assay except that after incubation with the sample, the immuno-adsorbent is incubated with a solution of labeled core polypeptide. The HTLV-III polypeptide can be 20 labeled with radioisotope, an enzyme, etc. for this type of assay.

In a third format, the bacterial protein, Protein A, which binds the  $F_c$  segment of an IgG molecule without interfering with the antigen-25 antibody interaction can be used as the labeled tracer to detect anti-HTLV-III-antibody adsorbed to the immunoadsorbent. Protein A can be readily labeled with a radioisotope, enzyme or other detectable species.

30 Some serum samples appear to show stronger reactivity towards HTLV-III core protein than toward

HTLV-III envelop protein. This suggests that combined testing for antibody against both viral core and envelop proteins might enhance the overall sensitivity of a test for HTLV-III infection. The 05 use of the combination of homogenous preparations of recombinant core and envelop protein, rather than the whole virus, for this purpose would eliminate false positives encountered with assays based on preparations of whole virus (which can contain host 10 cell contaminants). This would reduce the waste of valuable blood units.

A combination assay can be used based upon homogenous polypeptide pG2 and recombinant env protein. A suitable HTLV-III env protein is HTLV-III 15 polypeptide 121 described in United States Patent Application Serial Number 707,066, filed March 1, 1985, the teachings of which are incorporated by reference herein. A mixture of pG2 and polypeptide 121, preferably containing approximately equimolar 20 amounts of the two antigens, can be applied to a solid phase to form a double antigen immunoadsorbent for adsorption of antibody against either antigen. The assay would be conducted in the same manner as that described for the pG2 assay above.

25 Immunochemical assays employing recombinant HTLV-III core proteins for detection of antibodies against HTLV-III core protein have several advantages over those employing a whole (or disrupted) virus for this purpose. For one, assays based upon 30 the polypeptide will alleviate the concern over

growing large quantities of infectious virus and the inherent variability associated with cell culturing and virus production. Efficient expression of viral antigens in E. coli. as other host cell systems

05 provide a safe means of large scale production of assay reagents. Further, the assay will help mitigate the real or perceived fear of contracting AIDS by technicians in hospitals, clinics and blood banks who perform the test. As mentioned, reagents

10 for assays based upon the whole virus (e.g. whole virus antigen immunoabsorbent), even though they are made with a disrupted, inactivated virus, present a risk of contamination with live virus. For example, a possible source of live virus contamination may be

15 residual cell debris from the virus isolation process. Although extensive precautions can be taken to reduce the risk of contamination, it is virtually impossible to completely eliminate it. Significantly, the risk, though minimal, may be

20 perceived as greater than it actually is by persons who handle the test reagents. Assay reagents without whole virus can help minimize this perception of risk. Immunoassays based upon viral components in safe host cell systems provide a substitute

25 for assays based on the whole virus which are at least comparable in sensitivity and specificity and superior in reproducibility.

Assays employing natural, isolated HTLV-III core proteins, e.g. p24 protein, while they eliminate the use of whole virus from assay reagents, still require the growth of the virus on a large

scale for a supply of the natural protein and thus do not eliminate the risks attendant to this procedure.

05 The invention is illustrated further by the following Exemplifications.

Exemplification

Bacterial strains and plasmids

10 E. coli strain JA221 (1pp<sup>-</sup>) was used in all experiments as the host cell. Ghrayeb et al. (1984) EMBO J. 3. 2437-2442. Cells were grown in L-Broth supplemented with ampicillin (100 g/ml). The REV (Repligen, Cambridge, MA) expression vector was used for cloning of the HTLV-III DNA.

DNA manipulations

15 Isolation of plasmid DNA and various manipulations were carried out as previously described by L.C. Ghrayeb et al., i.e. supra. Restriction enzymes were obtained from New England Biolabs. T4 DNA ligase was purchased from Boehringer Mannheim 20 Biochemicals. The DNAs were digested with restriction enzymes in conditions described by the manufacturer.

Expression and analysis of the gag gene clones

25 HTLV-III gag proteins produced by recombinant clones PG1, PG2 and PG3 were analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) as described previously. See Chang, N. T. et al., (1985), Science, 228, 93-96. Cells were grown in 1 ml L-broth at 37°C overnight and the cells were

harvested by centrifugation at 5000 x g for 10 minutes. The cell pellets were dissolved in 200 ul of loading buffer and 20 ul was applied to a 12% SDS-polyacrylamide gel and electrophoresed under 05 reducing conditions. Unlabeled molecular weight markers were obtained from Biorad Laboratories.  $[^{14}\text{C}]$ -labeled molecular weight markers were obtained from Amersham. The expression of HTLV-III specific protein by the recombinant clones was detected by 10 Western blotting analysis using sera from AIDS patients. Bacterial proteins were separated on a 12% SDS-polyacrylamide gel and transferred to nitrocellulose and blotted as described below. The blot was incubated overnight at 4°C with sera from 15 AIDS patients or from healthy individuals. After washing, virus specific protein bands were visualized by incubation with  $[^{125}\text{I}]$ -labeled goat anti-human IgG (see below). The blots were air dried and exposed to Kodak X-AR5 at -70°C with intensifying 20 screens.

Purification of the pG2 protein

For large scale growth, 20 ml of an overnight culture of pG2 were inoculated into 1 liter of L-Broth containing 100  $\mu\text{g}/\text{ml}$  of ampicillin and 25 0.025% antifoam, and shaken at 37°C. The cells were harvested after 8 hr and washed with 50 mM Tris-HCl pH 8.5 (sonication buffer). 25 g of cell pellet were suspended in 70 ml of sonication buffer and sonicated in two portions at 70 W for eight 30 sec 30 bursts with a 60 sec cooling period between each

burst. The lysed cells were then centrifuged at 10,000 xg for 30 min. All of the pG2 protein was found in the pellet and constituted approximately 20% of the total protein as judged by SDS-PAGE.

05        The pellet containing the pG2 protein was suspended in 50 mM Tris-HCl pH 8.5 containing 8 M Urea, 1 M NaCl, 10 mM DL dithiothreitol (DTT) and 0.05% EDTA disodium salt (extraction buffer). The suspension was incubated at 45°C for 60 min and  
10        centrifuged at 10,000 xg for 30 min. The resulting supernatant was applied to a Sephacryl S-300 gel filtration column (5 x 80 cm) previously equilibrated with extraction buffer containing 5 mM DTT. The column was eluted in the same buffer at a flow  
15        rate of 0.5 ml/min at room temperature and the fractions (10 ml) were monitored by U.V. absorption at 280 nm. The pG2 protein, found in the second main peak, was pooled and dialyzed exhaustively against distilled water at 4°C. During dialysis,  
20        the pG2 protein was precipitated quantitatively. The precipitated protein was then redissolved in 10 ml of extraction buffer containing 10 mM DTT and incubated at 45°C for 30 min. The resulting solution was applied to a second Sephacryl S-300 column  
25        (2.6 x 65 cm) under identical conditions to the first column. The major peak contained the pG2 protein which was 95% pure as judged by SDS-PAGE. The protein was further purified by repeating the second column purification under identical conditions.  
30        The main peak from the third S-300 column contained the pG2 protein in 98% purity. The yield

was 50 mg and this preparation was used for screening human sera (see below).

Immunoreactivity of pG2 with Human Sera

50  $\mu$ g of pure pG2 protein or 430  $\mu$ g of purified 05 disrupted HTLV-III virus, were electrophoresed on a 12% SDS polyacrylamide gel (13 cm x 13 cm x 1.5 mm) and transferred to nitrocellulose using a Biorad Tran-Blot apparatus. The electroblotting buffer used was 20% aqueous methanol containing 0.016 M 10 Tris base and 0.13 M glycine, and transfer was performed at 40 volts at 4°C overnight. The nitrocellulose paper was then shaken for 2 hr at 37°C with 60 ml of PBS containing 5% non-fat dry milk, 0.1% sodium azide and 0.1% antifoam (milk buffer) 15 and then for 2 hrs at room temperature with 60 ml of 5% normal goat serum in milk buffer. At this stage, the blocked nitrocellulose was either stored at -20°C, or used directly for the strip assay. The nitrocellulose was cut into 13 cm x 0.5 cm strips, 20 and each strip was rocked overnight at 4°C with 4 ml of milk buffer containing 5% normal goat serum and 40  $\mu$ l of the human serum to be tested in a 15 ml disposable conical tube. The next day the milk solution was replaced with 10 ml of 0.15% sodium 25 deoxycholate, 0.1M NaCl, 0.5% triton X-100, 0.1 mM phenylmethylsulfonyl fluoride in 10 mM sodium phosphate pH 7.5 (wash buffer) and the tubes were rocked for 1 hr. The wash buffer was removed and replaced with 4ml 5% goat serum in milk buffer and 30 the tubes were rocked for 1 hr, at which time  $^{125}\text{I}$ -labeled goat anti-human IgG ( $10^6$  cpm/ml) was

added. After 30 min, the strips were washed for 1 hr with 10 ml of wash buffer, air dried and exposed to Kodak XAR-5 film at -70°C with intensifying screens.

05 Radioimmunoassay

96 well microtiter dishes were coated with the antigen at 100 $\mu$ g/ml in 50 mM Tris-HCl pH 8.0. After an overnight incubation, the wells were washed three times with phosphate buffered saline (PBS). The 10 wells were then post coated with 200  $\mu$ l 3% fish gelatin (Norland Products, Inc.) in PBS containing 0.1% sodium azide. The fish gelatin solution was removed and each well was filled with 200  $\mu$ l of 1:5 or 1:10 dilutions of the test serum in PBS containing 15 10% normal goat serum, 10% anti-E. coli goat serum and 1% fish gelatin. After one hour at room temperature, the wells were washed three times with PBS and 200  $\mu$ l of [ $^{125}$ I]-labeled goat anti-human IgG (Fc portion) in 1% normal goat serum, 1% fish 20 gelatin in PBS at  $1.5 \times 10^6$  cpm/ml was added to each well. After one hour at room temperature, the plates were washed four times with PBS and once with distilled water and counted.

RESULTS

25 Construction of the HTLV-III gag gene clones

The isolation of recombinant phage clone BH10 containing the unintegrated linear form of HTLV-III proviral DNA has been reported previously. Shaw et al., (1985), Science, 226, 1165-1171. The 9 Kb

HTLV-III insert of phage BH10 was released by SstI cleavage within the R element of the LTR (See Figure 1). The SstI fragment was then digested with either PvuII and BglII or PstI and BglII. The 949 bp

05 PvuII-BglII fragment and the 677 bp PstI-BglII fragments were inserted into the REV expression vector (Repligen, Cambridge, MA) to give pG1 and pG2 respectively (Figure 1). Clone pG3 was constructed from pG2. pG2 DNA was digested with PstI and

10 HindIII, end repaired and ligated. Thus, in pG3 the PstI-HindIII fragment was deleted from the HTLV-III DNA insert of pG2. As seen from Figure 1, the three constructs carry HTLV-III DNA that is predicted to code for chimeric peptides containing various

15 portions of the p17, p24 and p15 viral gag proteins. See Ratner et al., (1985), Nature, 313, 277-284. The sizes of the expressed proteins are larger than predicted since the expression vector supplies the initiation methionine codon plus 35 amino residues

20 at the NH<sub>2</sub>-terminus of each expressed protein.

Expression of the HTLV-III gag gene clones

E. coli transformed with plasmids, pG1, pG2 or pG3 were found to produce proteins of 41kd, 33kd and 18kd, respectively, as demonstrated by SDS-polacryl-  
25 amide gel electrophoresis of total bacterial cell lysates. SDS-PAGE analysis of HTLV-III gag gene proteins is shown in Figure 2. Cells from 1ml cultures were centrifuged and the pellets resuspended in 200 $\mu$ l of SDS sample buffer and analyzed by  
30 SDS-PAGE as described above. 20  $\mu$ l of cell lysate

were loaded per lane and gels were stained with commassie brilliant blue R250. (Lane 1, molecular weight markers, lane 2, control cells with no plasmid, lane 3, pG1, lane 4, pG2, lane 5, pG3, lane 05 6, cells carrying the REV vector containing no HTLV-III DNA. The number on the left designate the molecular weights in kilodaltons.)

All three proteins were made in large quantified (over 10% of total cellular protein in these 10 cells) but were not detected in the host cell with or without the REV vector alone. The overproduction of the plasmid encoded HTLV-III gag proteins caused a marked decrease in the rate of cell growth. The 15 kinetics of the growth rate could be correlated with the accumulation of the gag gene products in the cytoplasm although no cell lysis was observed (data not shown). Maximum accumulation was observed at 8 hours after the start of the log phase growth period. In addition, the expressed gag gene products 20 were present as aggregates containing membrane proteins after disruption of the cells. Depending on growth conditions, HTLV-III gag proteins of smaller size could be detected on SDS-PAGE gels (Figure 2). The products are likely due to the 25 degradation of the major high molecular weight gag proteins with increasing growth time.

Immunochemical characterization of the gag gene products

The bacterial expressed HTLV-III gag-specific 30 protein in cells carrying pG1, pG2 or pG3 were

detected by Western blot analysis using sera pooled from AIDS patients. The results of this analysis are shown in Figure 3. SDS-PAGE analysis was performed exactly as in Figure 2. Transfer of 05 proteins to nitrocellulose paper, reaction with antibodies and detection of immunoreactive bands is described above. Figure 3 shows a blot in which lane 1 is control cells, lane 2 is pG1, lane 3 is pG2 and lane 4 is pG3. The blot was treated with 10 pooled sera from AIDS patients. The numbers on the left designate the relative position of the [<sup>14</sup>C] molecular weight markers that were run along with the samples in lanes 1-4, but are not shown in the figure. The result clearly shows the synthesis of 15 specifically cross-reacting HTLV-III peptide in recombinant clones containing pG1, pG2 and pG3. The immunoreactive proteins in each clone corresponded to the expressed proteins, 41kd, 33kd, 18kd, seen in the Coomassie blue stained SDS-polyacrylamide gel 20 (Figure 2). There was no HTLV-III virion-specific peptide detected in lysate of control JA221 cells.

The products of pG2 was purified to greater than 98% homogeneity as judged by SDS-PAGE. Figure 4 shows SDS-PAGE analysis of pG2 purified as described above. PG-2 protein eluted from a sephacryl S-300 column in 50 mM Tris-HCL pH 8.5 containing 8M Urea, 1M NaCl and 5 mM DTT, was mixed with an equal volume of 2X SDS-PAGE sample buffer, heated at 100°C for 5 min and applied to two identical 12% SDS-PAGE 30 gels. One of the gels was stained with Coomassie Brilliant Blue (panel A), while the other trans-

ferred to nitrocelloose and the blot treated with pooled sera from AIDS patients (panel B) as in Figure 3. Panel A, lane 1 is molecular weight markers, lane 2, 3, 4 are pure pG2 at 2, 5 and 10 05 g respectively. Panel B is identical to A except that lane 1 was run with <sup>14</sup>[C]-labeled molecular weight markers.

The major band is of 33 kd while there is a minor band of 30 kd which is also seen in total cell 10 lysates (Figure 2) and is most likely a degradation product. A very minor band of 65 kd can also be seen and is most likely to be the dimer form of pG2. All the bands that are visible by Commassie blue 15 staining are also immunoreactive towards HTLV-III specific antibodies present in sera from AIDS patients (Figure 4B) as well as the anti-P24 mouse monoclonal antibody (data not shown). We feel confident that the pG2 protein is essentially free of contaminating E. coli. proteins.

20 The purified pG2 protein was used to screen for antibodies directed towards the core p24 protein in human sera, using a strip assay based on the western blot technique. The same samples were also tested under identical conditions, using the purified, 25 disrupted HTLV-III virus. The results are summarized in Table 1.

Table 1

| Clinical Status      | No. Tested | No. Positive        |              | No. Positive Using pG2 |
|----------------------|------------|---------------------|--------------|------------------------|
|                      |            | For p24 of HTLV-III | No. Positive |                        |
| Healthy donors       | 50         | 0                   | 0            |                        |
| Healthy homosexuals* | 49         | 17                  | 17           |                        |
| ARC**                | 51         | 28                  | 28           |                        |
| AIDS**               | 34         | 19                  | 19           |                        |

\*Only 21 of these donors were seropositive for antibodies to either p24 and/or gp41 of HTLV-III. In addition, the same individuals who were positive for p24 antibodies using the whole virus assay were also positive for antibodies to pG2.

\*\*All these sera were positive for antibodies to gp41.

The results show that there is 100% correlation

10 between p24 antibodies detected by pG2 protein and those detected by the whole virus. In addition, none of the normal donor controls were reactive with pG2 protein. This indicates the recombinant pG2 protein can substitute adequately for the whole

15 virus when detection of p24 antibodies is required. The data presented in Table 1 also show that of the 21 seropositive healthy homosexuals tested, 17 (81%) had detectable antibodies to the p24. In both ARC and AIDS patients, the percentage drops to 56%.

20 Whether the anti-p24 antibody titer is an indication of the progress of HTLV-III infection remains to be studied. In this regard, the uses of pG2 protein in such studies would be preferable since the levels of p24 protein in different virus preparations may vary

25 and may affect the sensitivity of the assay.

Partially purified pG2 protein was tested in a solid phase RIA. Details of the plate RIA assay are given above. The pG2 protein preparation used was only "partially" purified. 24 sera from AIDS/ARC 05 patients and 24 sera from healthy individuals were used in the assay and results were plotted on a semi-log scale. The horizontal dotted line designates the cut-off points so that values below the line are considered negative while those above are 10 considered positive. The results are shown in Figure 6. The results indicated that 18 out of the 24 AIDS or ARC patients' sera tested were reactive with the antigen. The 6 sera from patients with AIDS or ARC that were negative in the RIA assay were 15 found to contain no detectable amounts of anti-p24 antibodies as assayed by a strip immunoassay base on Western blot technique using the purified disrupted whole virus (data not shown). Of the 24 normal human sera tested in the RIA, only one was positive 20 but was negative when tested with the purified virus in a Western blot (data not shown). The reactivity of the one normal sample may be due to the presence of unusually high titre of anti-E. coli antibodies present in that particular serum and the fact that 25 the pG2 antigen preparation contained trace amounts of E. coli protein impurities. This nonspecific immunoreactivity can be eliminated by absorption of this serum with Sepharose 4B conjugated with E. coli extract. Alternatively, better purified pG2 prepara- 30 tions such as the preparation used in the strip assay can be used.

Equivalents

Those skilled in the art will recognize, or be able to ascertain no more than routine experimentation, many equivalents to the specific embodiments 05 of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

CLAIMS

1. A method of detecting antibody against HTLV-III core protein in a biological fluid, comprising the steps of:

05 a. providing an antigen immunoadsorbent comprising a solid phase to which is attached a recombinant HTLV-III core antigen immunoreactive with antibody against HTLV-III core protein;

10 b. incubating the immunoadsorbent with a sample of the biological fluid to be tested under conditions which allow antibody in the sample to complex with the antigen immunoadsorbent;

15 c. separating the immunoadsorbent from the sample; and

d. determining antibody bound to the immunoadsorbent as an indication of antibody against HTLV-III core protein in

20 the sample.

2. A method of Claim 1, wherein the recombinant HTLV-III core antigen is a chimeric antigen consisting essentially of antigenic portions of HTLV-III p24 and p17 proteins.

25 3. A method of Claim 1, wherein the recombinant HTLV-III antigen is the pG1, pG2 or pG3 polypeptide.

4. A method of Claim 1, wherein the biological fluid is human serum or plasma.
5. A method of Claim 1, wherein the step of determining the antibody bound to the immuno-  
05 adsorbent comprises:
  - a) incubating the immunoadsorbent with a labeled antibody against immunoglobulin of the species from which the biological fluid is derived;
  - 10 b) separating the immunoadsorbent from the labeled antibody; and
  - c) detecting the label associated with the immunoadsorbent as an indication of antibody against HTLV-III core protein in the sample.
- 15 6. A method of Claim 5, wherein the biological fluid is human plasma or serum, and the labeled antibody is labeled anti-human Ig antibody.
7. A method of detecting antibody against HTLV-III core protein in human plasma or serum, comprising the steps of:  
20
  - a) providing an antigen immunoadsorbent comprising a polystyrene bead coated with an essentially homogeneous purified preparation of pG2 polypeptide;
  - 25 b) incubating the immunoadsorbent with a sample of human plasma or serum under conditions which permit anti-HTLV-III core protein

antibody in the sample to complex with the pG2 polypeptide;

c) separating the immunoadsorbent from the sample;

05 d) incubating the immunoadsorbent with a solution of labeled anti-human Ig antibody;

e) separating the immunoadsorbent from the solution of labeled antibody; and

10 f) detecting the label associated with the immunoadsorbent as an indication of anti-HTLV-III core protein antibody in the sample.

8. An immunoadsorbent comprising a solid phase support having attached thereto a recombinant HTLV-III core protein immunoreactive with antibody against HTLV-III core protein.

15 9. An immunoadsorbent of Claim 8, wherein the recombinant core protein is a chimeric protein consisting essentially of antigenic regions of the HTLV-III p24 and p17 protein.

20 10. An immunoadsorbent of Claim 8, wherein the recombinant HTLV-III core protein is pG2 polypeptide.

11. An assay for antibody against HTLV-III in a biological fluid comprising the steps of:

25 a) providing an immunoadsorbent comprising a solid phase to which is attached mixture of recombinant HTLV-III core protein

immunoreactive with antibody against HTLV-III core proteins and recombinant HTLV-III envelop protein immunoreactive with antibody against HTLV-III envelop protein;

- 05      b)    incubating the immunoadsorbent with a sample of biological fluid;
- c)    separating the immunoadsorbent from the sample; and
- d)    determining antibody bound to the immuno-adsorbent as an indication of antibody against HTLV-III in the sample.

12. A method of Claim 11, wherein the recombinant core protein is selected from the group consisting of pG1, pG2 and pG3 and the recombinant envelop protein is HTLV-III polypeptide 121.

15


13. An assay for antibody against HTLV-III in a biological fluid, comprising the steps of:

- 20      a)    providing an immunoadsorbent comprising a solid phase to which is attached approximately an equal amount of pG2 polypeptide and HTLV-III polypeptide 121;
- b)    incubating the immunoadsorbent with a sample of biological fluid;
- c)    separating the immunoadsorbent from the sample; and
- d)    incubating the immunoadsorbent with a solution of anti-human Ig antibody;
- e)    separating the immunoadsorbent from the sample;

f) detecting the label associated with the immunoadsorbent as an indication of anti-HTLV-III antibody in the sample.


14. An immunoadsorbent comprising a solid phase 05 coated with an equal amount of pG2 polypeptide and polypeptide 121.
15. A recombinant HTLV-III core antigen immunoreactive with antibody against HTLV-III core protein.
- 10 16. A HTLV-III core antigen of Claim 1 which is a chimeric antigen consisting essentially of antigenic portions of HTLV-III p24 and p17 proteins.
17. PG2 polypeptide.
- 15 18. An essentially homogenous preparation of pG2 protein.

FIGURE 1




2/6

FIGURE 2



3/6


FIGURE 3



14 —

4/6

FIGURE 4



5/6

## FIGURE 5

33 amino acids from REV vector

|              |
|--------------|
| GCAGAAATGGGA |
| AlaGluIrpA10 |


TAGAGTACATCCAGTGCATGCAGGGCTATGCCACGCCAGATGAGAGAACCAAGGGOAAGTGACATACCAAGG  
 ArgValHisProValHisAlaGlyProIleAlaProGlyGlnMetArgGluProArgGlySerAspIleAlaGly  
  
 AACTACTAGTACCCCTCAGGAACAAATAGGATGGATGACAAATAATCCACCTATCCCAGTAGGAGAAATTATCAA  
 ThrThrSerIhrLeuGlnGluGlnIleGlyIrpMetThrAsnAsnProProIleProValGlyGluIleIvrlys  
  
 AAGATGGATAATCCTOOGATTAATAAAATACTAAAGAATGTATAGCCCTACCAGCATCTGGACATAAGACAAGG  
 ArgIrpIleIleLeuGlyLeuAsnLysIleValArgMetTyrSerProThrSerIleLeuAspIleArgGlnGly  
  
 ACCAAAAGAACCTTTAGAGACTATGTAGACCCGGTTCTATAAAACTCTAAAGAGCCGAGCAAGCTTCACAGGAGGT  
 ProLysGluProPheArgAspIyrValAspArgPheIyrlysIhrLeuArgAlaGluGlnAlaSerGlnGluVal  
  
 AAAAATGGATGACAGAACCTGTTGGTCCAAAATGCGAACCCAGATTGTAAGACTATTTAAAGCATGGG  
 LysAsnIrpMetThrGluIhrLeuLeuValGlnAsnAlaAsnProAspCysLysIhrIleLeuLysAlaLeuGly  
  
 ACCAGCGGCTACACTAGAAGAAATGATGACAGCATGTCAGGGAGTAGGGAGGCCATAAGGCAAGAGTTT  
 ProAlaAlaIhrLeuGluGluMetMetThrAlaCysGlnGlyValGlyGlyProGlyHisLysAlaArgValLeu  
  
 GGCTGAAGCAATGAGCCAAAGTAACAAATACAGCTACCCATAATGATGCAGAGAGGCAATTAGGAAACCAAGAAA  
 AlaGluAlaMetSerGlnValIhrAsnThrAlaIhrIleMetMetGlnArgGlyAsnPheArgAsnGlnArgLys  
  
 GATGGTTAAGTGTTCATTGIGCAAAGAAUGGCACACAGCCAGAAATTGCAGGGCCCTAGGAAAAAGGGCTG  
 MetValLysCysPheAsnCysGlyLysGluGlyHisIhrAlaArgAsnCysArgAlaProArgLysLysGlyCys

TTGGAAAATGTGGAAAGGAAGGACACCAAATGAAAGATTGACTGAGAGACAGGCTAAATTAGGAAAUATC  
 TrpLysCysGlyLysGluGlyHisGlnMetLysAspCysIhrGluArgGlnAlaAsnPheLeuGlyIle

14 amino acids from REV vector

6 / 6

FIGURE 6



# INTERNATIONAL SEARCH REPORT

International Application No PCT/US 87/00373

## I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) \*

According to International Patent Classification (IPC) or to both National Classification and IPC  
 4 G 01 N 33/569; G 01 N 33/543; C 12 N 15/00;  
 IPC : C 12 P 21/00; C 07 K 15/00

## II. FIELDS SEARCHED

### Minimum Documentation Searched \*

| Classification System  | Classification Symbols         |
|--|--------------------------------|
| IPC <sup>4</sup>   | G 01 N; C 12 Q; C 12 N; A 61 K |
| Documentation Searched other than Minimum Documentation<br>to the Extent that such Documents are Included in the Fields Searched * |                                |

## III. DOCUMENTS CONSIDERED TO BE RELEVANT \*

| Category * | Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>   | Relevant to Claim No. <sup>13</sup>                      |
|------------|--|--|
| P,X<br>A   | WO, A, 86/06099 (GENETIC SYSTEMS CORPORATION) 23 October 1986, see the whole document  | 1,2,5,6,8,<br>9,11,15,16<br>3,4,7,10,<br>12-14,17,<br>18 |
| P,X        | Chemical Abstracts, vol. 104, no. 25, 23 June 1986 (Columbus, Ohio, USA), J. Ghayeb et al., "Human T-cell lymphotrophic virus type III (HTLV-III) core antigens: synthesis in Escherichia coli and immunoreactivity with human sera", see page 170, abstract no. 220096s | 1-18   |
| P,X<br>A   | EP, A, 0181150 (CHIRON CORPORATION) 14 May 1986, see abstract; claims 1,6-11   | 1,2,5,6,8,9,<br>11,15,16<br>3,4,7,10,<br>12-14,17,18     |
|            |  | ./.  |

\* Special categories of cited documents: <sup>10</sup>

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

9th June 1987

Date of Mailing of this International Search Report

16 JUL 1987

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

M. VAN MOL

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

| Category * | Citation of Document, with indication, where appropriate, of the relevant passages  | Relevant to Claim No |
|------------|---|----------------------|
| X          | Proceedings of the National Academy of Sciences of the USA, vol. 82, no. 22, no. 22, November 1985 (Washington, USA), D.J. Dowbenko et al., "Bacterial expression of the acquired immunodeficiency syndrome retrovirus p24 gag protein and its use as a diagnostic reagent", page 7748, see the whole article<br>-- | 1,8                  |
| P,A        | EP, A, 0199438 (T.W. CHANG et al.) 29 October 1986, see abstract; claims<br>-----   | 11-14                |

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON

---

INTERNATIONAL APPLICATION NO. PCT/US 87/00373 (SA 16297)

---

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 29/06/87

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

---

| Patent document cited in search report | Publication date | Patent family member(s)  | Publication date                             |
|--|------------------|--|--|
| WO-A- 8606099                          | 23/10/86         | EP-A- 0201716<br>AU-A- 5572786<br>AU-A- 5669086<br>EP-A- 0220234 | 20/11/86<br>16/10/86<br>05/11/86<br>06/05/87 |
| EP-A- 0181150                          | 14/05/86         | JP-A- 61173782   | 05/08/86                                     |
| EP-A- 0199438                          | 29/10/86         | None   |  |

---